|
Mechanism5-HT1B receptor antagonists [+5] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of XC130-A10H in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, parallel-group single ascending dose (SAD) study. Up to 5 cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation. In each cohort, subjects will receive a single oral dose of XC130-A10H or matching placebo on Day 1. Safety, tolerability, and pharmacokinetics will be assessed throughout the study. Dose escalation will not take place until the Principal Investigator, Sponsor, and Medical Monitor have determined that adequate safety and tolerability from the previous cohorts have been demonstrated to permit proceeding to the next cohort.
100 Clinical Results associated with 5-HT2A receptor x D3 receptor x 5-HT1B receptor x 5-HT2B receptor x A1R x D2 receptor
100 Translational Medicine associated with 5-HT2A receptor x D3 receptor x 5-HT1B receptor x 5-HT2B receptor x A1R x D2 receptor
0 Patents (Medical) associated with 5-HT2A receptor x D3 receptor x 5-HT1B receptor x 5-HT2B receptor x A1R x D2 receptor